Patients can explore options like the Medicare Prescription Payment Plan (M3P) to spread out prescription costs
Semaglutide side effects are well-documented and often manageable with slow titration and dietary adjustments
Does semaglutide GLP-1 get rid of belly fat
Cagrilintide is a long-acting amylin analogue with dual amylin and calcitonin receptor activity, whereas semaglutide is a once-weekly GLP-1 receptor agonist with robust anti-hyperglycemic and appetite-suppressing effects
To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
Recently, Ozempic has also gained widespread attention as a weight-loss drug due to its appetite-suppressing effects, despite this not being its FDA-approved use
